TDP-43 misfolding and aggregation occurs as primary pathology in ALS/FTD (~95% and ~50% respectively) and as secondary pathology in AD (LATE-ND, 20-50%) and PD (10-15%). The investable thesis is NOT pan-NDD unification but precision stratification: TDP-43-positive ALS/FTD and LATE-ND subgroups. ASOs, aggregation blockers, and nuclear localization stabilizers are viable approaches. The tofersen precedent (accelerated approval for SOD1-ALS based on NfL reduction) demonstrates biomarker-driven deve
Shared mechanism across ALS, FTD, AD/LATE: Nuclear TDP-43 loss impairs RNA splicing and axonal maintenance; the same mislocalized protein forms ubiquitinated cytoplasmic aggregates in ALS/FTD and limbic TDP-43 pathology in AD/LATE, producing disease-specific vulnerable cell loss through a shared RNA-proteostasis bottleneck.
Falsifiable prediction: Restoring nuclear TDP-43 localization in TARDBP iPSC motor neurons and AD/LATE hippocampal neurons should normalize STMN2-like splicing markers and r
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
TARDBPAxonal Transport CytoskeletonProtein Aggregation
Convergent signals
TARDBP recurs across 2 selected hypotheses with aligned directionality in axonal transport cytoskeleton, protein aggregation.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
7/11
dimensions won
TDP-43 Proteinopathy as a Cross-Disease
6/11
dimensions won
TDP-43 RNA-proteostasis failure across A
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.65
0.92
Evidence
0.75
0.86
Novelty
0.60
0.82
Feasibility
0.68
0.68
Impact
0.65
0.86
Druggability
0.55
0.00
Safety
0.50
0.00
Competition
0.65
0.00
Data
0.75
0.00
Reproducible
0.70
0.00
KG Connect
0.50
0.50
Score Breakdown
Dimension
TDP-43 Proteinopathy as a Cros
TDP-43 RNA-proteostasis failur
Mechanistic
0.650
0.920
Evidence
0.750
0.860
Novelty
0.600
0.820
Feasibility
0.680
0.680
Impact
0.650
0.860
Druggability
0.550
0.000
Safety
0.500
0.000
Competition
0.650
0.000
Data
0.750
0.000
Reproducible
0.700
0.000
KG Connect
0.500
0.500
Evidence
TDP-43 Proteinopathy as a Cross-Disease Pathological Substra
No evidence citations yet
TDP-43 RNA-proteostasis failure across ALS, FTD, and AD/LATE
No evidence citations yet
Debate Excerpts
TDP-43 Proteinopathy as a Cross-Disease Pathologic
# Critical Evaluation of Cross-Disease Neurodegeneration Hypotheses
## Hypothesis 1: Autophagy-Lysosomal Pathway Dysfunction
### Weak Links
1. **Correlation vs. Causation Problem**: Much supporting...
Persona-Domain Expert
**Bottom Line**
Most feasible near-term development paths are not “one drug for AD/PD/ALS/FTD.” The tractable version is mechanism-stratified development: use cross-disease biology to nominate biomar...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "Autophagy-Lysosomal Pathway Dysfunction as a Unifying Proteostasis Failure",
"description": "Impaired autophagic flux and lysosomal degradation c...
TDP-43 RNA-proteostasis failure across ALS, FTD, a
# Critical Evaluation of Cross-Disease Neurodegeneration Hypotheses
## Hypothesis 1: Autophagy-Lysosomal Pathway Dysfunction
### Weak Links
1. **Correlation vs. Causation Problem**: Much supporting...
Persona-Domain Expert
**Bottom Line**
Most feasible near-term development paths are not “one drug for AD/PD/ALS/FTD.” The tractable version is mechanism-stratified development: use cross-disease biology to nominate biomar...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "Autophagy-Lysosomal Pathway Dysfunction as a Unifying Proteostasis Failure",
"description": "Impaired autophagic flux and lysosomal degradation c...